Matrisome Bio
- Biotech or pharma, therapeutic R&D
Matrisome Bio is the world leader in harnessing the distinctive properties of the extracellular matrix (ECM) to revolutionize targeted therapies across chronic disease. Extracellular matrix, the scaffolding that surrounds all cells in the body, becomes dysregulated and dysfunctional in a wide range of disease states. Matrisome’s unique capabilities, developed in the MIT lab of Richard O. Hynes, PhD (2022 Lasker Award), enable comprehensive characterization of the ECM to identify novel therapeutic targets and develop proprietary, ECM-targeted therapeutics that address the array of indications associated with changes in the ECM. Matrisome Bio’s initial therapeutic focus is metastatic, solid tumor oncology, with ongoing research expansion into additional indications beginning with various types of fibrosis. Matrisome Bio’s approach is modality-agnostic and includes radioligand therapies (RLTs), antibody-drug conjugates (ADCs), tethered cytokines and CAR-T approaches.
Address
CambridgeMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}